Olaptesed Pegol
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Olaptesed Pegol
- DrugBank Accession Number
- DB11707
- Background
Olaptesed Pegol has been investigated for the treatment of Hematopoietic Stem Cell Transplantation.
- Type
- Small Molecule
- Groups
- Investigational
- Synonyms
- Olaptesed Pegol
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAntihemophilic factor (recombinant), PEGylated The therapeutic efficacy of Olaptesed Pegol can be decreased when used in combination with Antihemophilic factor (recombinant), PEGylated. Certolizumab pegol The therapeutic efficacy of Olaptesed Pegol can be decreased when used in combination with Certolizumab pegol. Damoctocog alfa pegol The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Olaptesed Pegol. Elapegademase The therapeutic efficacy of Elapegademase can be decreased when used in combination with Olaptesed Pegol. Lipegfilgrastim The therapeutic efficacy of Lipegfilgrastim can be decreased when used in combination with Olaptesed Pegol. - Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- MTM792B442
- CAS number
- 1390628-22-4
References
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Chronic Lymphocytic Leukemia 1 2 Not Yet Recruiting Treatment Pancreatic Metastatic Cancer 1 1 Completed Treatment Autologous Stem Cell Transplantation 1 1 Completed Treatment Hematopoietic Stem Cell Transplantation (SCT) 1 1, 2 Active Not Recruiting Treatment High Grade Glioma: Glioblastoma (GBM) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
- Not Available
- Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at October 20, 2016 20:41 / Updated at January 14, 2023 19:03